RS20060323A - Substituted indole-o-glucosides - Google Patents

Substituted indole-o-glucosides

Info

Publication number
RS20060323A
RS20060323A YUP-2006/0323A YUP20060323A RS20060323A RS 20060323 A RS20060323 A RS 20060323A YU P20060323 A YUP20060323 A YU P20060323A RS 20060323 A RS20060323 A RS 20060323A
Authority
RS
Serbia
Prior art keywords
glucosides
substituted indole
indole
substituted
diabetes
Prior art date
Application number
YUP-2006/0323A
Other languages
Serbian (sr)
Inventor
Mona Patel
Xiaoyan Zhang
Philip Rybczynski
Maud Urbanski
Mary Pat Beavers
Original Assignee
Janssen Pharmaceutica N.V.,
Tanabe Seiyaku Co.Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V.,, Tanabe Seiyaku Co.Ltd., filed Critical Janssen Pharmaceutica N.V.,
Priority claimed from PCT/US2004/024674 external-priority patent/WO2005012243A2/en
Publication of RS20060323A publication Critical patent/RS20060323A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.
YUP-2006/0323A 2003-11-12 2004-07-30 Substituted indole-o-glucosides RS20060323A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51915503P 2003-11-12 2003-11-12
US57975804P 2004-06-15 2004-06-15
PCT/US2004/024674 WO2005012243A2 (en) 2003-08-01 2004-07-30 Substituted indole-o-glucosides

Publications (1)

Publication Number Publication Date
RS20060323A true RS20060323A (en) 2008-08-07

Family

ID=40433444

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2006/0323A RS20060323A (en) 2003-11-12 2004-07-30 Substituted indole-o-glucosides

Country Status (2)

Country Link
EC (1) ECSP066628A (en)
RS (1) RS20060323A (en)

Also Published As

Publication number Publication date
ECSP066628A (en) 2006-10-25

Similar Documents

Publication Publication Date Title
RS20060320A (en) Substituted indazole-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2005012318A3 (en) Substituted fused heterocyclic c-glycosides
EG24978A (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment.
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
PL1682530T3 (en) Pyrrole substituted indoles as inhibitors of pai-1
AU2003247798A1 (en) Nozzles and components thereof and methods for making the same
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
NO20055130L (en) Aminocyclohexyl ether compounds and their use
UA86591C2 (en) Pyrrolodihydroisoquinolines as pde10 inhibitors, pharmaceutical composition based thereon
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
ZA200604874B (en) Pharmaceutical compositions
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
UA83203C2 (en) Thiazol-(bi)cycloalkyl-carboxanilides and their use for fighting against undesirable microorganisms
DE60316128D1 (en) N-sulfonylurea APOPTOSIS PROMOTERS
MX2007004461A (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use.